Citations

Clear

6273 citation(s) found for "To, Andrew".

Extracorporeal Membrane Oxygenation for Pneumocystis Pneumonia: Outcomes in Patients From the Extracorporeal Life Support Organization
Henry, Kyle J., Ham, Kealy, Cartin-Ceba, Rodrigo, Khattar, Georges , D’Cunha, Jonathan, Sen, Ayan, Patel, Bhavesh, Pulsipher, Aaron M. , Thompson, Emily , Thompson, Emily R , D'Cunha, Jonathan, Pulsipher, Aaron M , Thompson, Emily R., Vikram, Holenarasipur R. , Cartin‐Ceba, Rodrigo , Limper, Andrew H.

Mayo Clinic

Critical Care Explorations | May 5, 2026 | Volume: 8 | Issue: 5 | Pages: e1414

10.1097/cce.0000000000001414 | PMID 42084230 Get It

OBJECTIVES: Pneumocystis jirovecii pneumonia (PCP) can cause severe hypoxemic respiratory failure in immunocompromised patients. Contemporary outcomes of venovenous extracorporeal membrane oxygenation (VV ECMO) support for PCP are poorly characterized, and existing reports are limited to small case series. DESIGN: Retrospective cohort study. SETTING: International registry study using the Extracorporeal Life Support Organization (ELSO) registry. PATIENTS/SUBJECTS: Adults with PCP-associated hypoxemic respiratory failure supported with VV ECMO between 2011 and 2024. INTERVENTIONS: VV ECMO. MEASUREMENTS AND MAIN RESULTS: A total of 209 patients with PCP-associated respiratory failure supported with VV ECMO were identified. The overall in-hospital mortality was 60.8%. Survivors were younger than nonsurvivors (median age 41.9 vs. 46.8 yr; p = 0.047). Duration of mechanical ventilation before VV ECMO was longer among nonsurvivors (median 4.7 vs. 1.6 d; p = 0.019). The proportion of patients with HIV infection was similar among survivors and nonsurvivors (19.5% vs. 22.1%; p = 0.73). Pre-ECMO vasopressor use, prone positioning, and renal replacement therapy were common and did not differ between groups. Clinical course was characterized by prolonged VV ECMO support (median 18.6 d) and frequent complications, including pneumothorax (21.1%), renal replacement therapy during VV ECMO (31.6%), intracranial hemorrhage or stroke (7.7%), and major pulmonary or gastrointestinal hemorrhage (16.8%). PCP accounted for a small proportion of VV ECMO runs reported to the ELSO registry throughout the study period at 0.36% of reported cases. No significant temporal trend in mortality was observed. CONCLUSIONS: PCP-associated respiratory failure supported with VV ECMO is associated with substantial mortality and prolonged VV ECMO support. These findings provide contemporary benchmarks that may inform VV ECMO candidacy discussions and expectations in this challenging patient population.
The burden and outcomes of vaccine-preventable infections among adult congenital heart disease patients: a nationwide analysis
Hamza, Izhan, Kalaiger, Abdul M., Khalid, Salman , Ellauzi, Rama , Abdulla, Amer , Chatila, Khaled, Aftab, Abdullah, Kethineni, Mounisha, Goldsweig, Andrew, Kalaiger, Abdul Mukhtadir , Mansoor, Taha , Ismayl, Mahmoud , Chatila, Khaled , Goldsweig, Andrew M.

Mayo Clinic

Baylor University Medical Center Proceedings | May 4, 2026 | Volume: 39 | Issue: 4 | Pages: 600-607

10.1080/08998280.2026.2661560 | PMID 42269044 Get It

In situ impedance analysis device for clot characterization in large vessel occlusion acute ischemic stroke, a first-in-human study
Cheung, Andrew , Rice, Henry, Villiers, Laetitia de , Manning, Nathan , Saleme, Suzana, Forestier, Géraud , Lafaurie-Janvore, Julie, Rambeau, Joachim, Bozsak, Franz, Kadirvel, Ramanathan , Doyle, Karen, Brinjikji, Waleed, Liebeskind, David S. , Cordato, Dennis, de Villiers, Laetitia , Manning, Nathan W , Forestier, Géraud , Rambeau, Joachim , Kadirvel, Ram , Liebeskind, David S. , Rouchaud, Aymeric , Cordato, Dennis , Rice, Henry, Saleme, Suzana , Nascimento, Vinicius Carraro do , Doyle, Karen , Brinjikji, Waleed , Rouchaud, Aymeric

Mayo Clinic

Journal of NeuroInterventional Surgery | May 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: jnis-2025-024772

10.1136/jnis-2025-024772 | PMID 42070796 Get It

Background Large vessel occlusion (LVO) stroke is associated with a high risk of permanent disability. There are no reliable tools providing periprocedural information on clot characteristics, such as composition and length, that may impact first pass effect, which has been shown to improve functional outcomes. In the first study of a novel technology, we evaluated whether the Clotild Smart Guidewire System (Clotild), an impedance-based device, can provide in situ information on clot characteristics during a mechanical thrombectomy procedure. Methods This is the first-in-human, international, multicentric, single-arm trial involving LVO stroke patients. Of 45 enrolled subjects, 41 constituted the safety population; 39 was the per protocol population, of which 26 subjects with complete impedance data comprised the performance population. The latter was divided into development (11 subjects) and validation (15 subjects) populations for prediction model development and assessment. The safety endpoint assessed Clotild-related intracranial vessel perforation/dissection. Performance endpoints evaluated Clotild’s ability to perform classification of impedance measurements distinguishing substantial versus negligible local content in red blood cells (RBCs) and platelets, to detect the arterial wall and the distal end of the clot. Results The safety endpoint was met in all subjects. Performance analysis comparing the agreement between Clotild’s output and impedance experts’ readings showed an area under the receiver operating characteristic curve (AUC) of 0.97 (95% CI 0.93 to 0.99) for RBC, and 0.94 (95% CI 0.89 to 0.98) for platelet clot composition. Regarding detection, Clotild’s performance showed an AUC of 0.69 (95% CI 0.59 to 0.77) for the arterial wall, and 0.83 (95% CI 0.59 to 1.00) for the distal end of the clot. Conclusions Clotild was proven safe to acquire impedance data and to provide information on in situ clot characteristics in large vessel occlusions.
Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma
Ren, Zexin , Zhao, Zixuan , Cowan, Andrew J, Ma, Will , Xie, En , Shi, Qian, Shi, Qian , Cowan, Andrew J , Xie, En , Shi, Qian , Cowan, Andrew J.

Mayo Clinic

Cancer Research Communications | May 2, 2026 | Volume: 6 | Issue: 5 | Pages: 1206-1212

10.1158/2767-9764.crc-25-0393 | PMID 42068235 Get It

Abstract Minimal residual disease (MRD) has been endorsed by the FDA Oncology Drugs Advisory Committee as an endpoint for accelerated approval in multiple myeloma based on individual patient data collected from randomized trials. However, emerging data from recent trials were not included. A novel artificial intelligence (AI)–assisted framework is proposed, which automates information identification and extraction, providing up-to-date analyses that confirm moderate trial-level and strong individual patient–level associations between MRD− rates at suspected complete response (MRD-CR) and survival endpoints in multiple myeloma. Specifically, this study utilized an AI-assisted framework that identifies relevant studies and filters critical information to analyze published data via 2 independent objectives. First, we examined the trial-level association using the coefficients of determination (R2) and its 95% confidence intervals (CI) based on published statistics of treatment effects on MRD and various endpoints. Next, we generated synthetic individual patient data with covariates through AI-curated tools to estimate the individual-level association. The AI tool searched for eligible randomized clinical trials (RCT). A total of 20 two-arm comparisons from 19 RCTs were analyzed. Trial-level analysis showed an R2 of 0.71 (95% CI, 0.52–0.89) pooling disease subpopulations. Furthermore, AI techniques were applied to create synthetic individual data, combining information extracted from Kaplan–Meier curves and subgroup analyses from published literatures. Using generated synthetic data, we estimated the individual-level correlation between MRD-CR rates and progression-free survival outcomes with a bivariate copula model and calculated a global odds ratio of 7.28 (95% CI, 5.60–8.95). Significance: (i) A novel AI-assisted framework is proposed, which automates information identification and extraction, providing rapid up-to-date analyses. (ii) Moderate trial-level and strong individual patient–level associations between MRD and various clinical endpoints in multiple myeloma are confirmed.
Pathogenic PF4 /Polyanion ELISA ‐Negative Antibodies in HIT
Kanack, Adam J. , Splinter, Noah P., Mauch, Emily, Gil, Morayma Reyes, Jasra, Sakshi , Goodwin, Andrew, Smock, Kristi J. , Ahmad, Hadiyah, Ashrani, Aneel A. , Robinson, Nathaniel L. , Jones, Curtis G., Pechauer, Shannon M., yttre, erin , Aster, Richard H. , Kohlhagen, Mindy , Leger, Rachel, Johns, Gretchen, Murray, David , Zhou, Lu, Wang, Demin, Wen, Renren , Chen, Dong, Pruthi, Rajiv K. , Padmanabhan, Anand , Wang, Demin , Zhou, Lu , Mauch, Emily E, Smock, Kristi J , Kohlhagen, Mindy C, Leger, Rachel R, Chen, Dong , Padmanabhan, Anand , Wang, Demin , Tefera, Leben T. , Gil, Morayma Reyes , Casanegra, Ana I. , Johns, Gretchen S., Zhou, Lu

Mayo Clinic

American Journal of Hematology | May 2, 2026 | Volume: 101 | Issue: 8 | Pages: 1790-1798

10.1002/ajh.70333 | PMID 42068120 Get It

ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT. Once HIT is ruled out, alternative, non‐heparin‐based anticoagulant treatments are ceased, and heparin reintroduction frequently occurs. Methods Antigen‐based and PF4‐dependent functional testing were used to study PF4/polyvinylsulfonate ELISA‐negative platelet‐activating antibodies in HIT‐suspected patients. Results Three patients with clinical presentations consistent with HIT tested negative in an ELISA using PF4‐polyvinylsulfonate (PF4/PVS), an antigenic target very commonly used for HIT antibody screening. All three patients demonstrated PF4‐dependent platelet activation in functional testing that was sensitive to blockade of platelet FcγRIIa receptors and inhibited by high concentrations of heparin, consistent with pathogenic HIT antibodies. Functional testing‐based screening of 500 ELISA‐negative patients identified three additional patients whose sera activated platelets in a PF4‐ and FcγRIIa‐dependent manner and had clinical histories consistent with HIT. Five of the six ELISA‐negative HIT patients were re‐exposed to heparin, which precipitated a decrease in platelet counts in all re‐exposed patients, and one patient developed a new thrombus. Conclusions Recognition of ELISA‐negative HIT is critical to avoid harm due to the cessation of alternative anticoagulation therapy and re‐exposure of these patients to heparin.
De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis
Miller, R., Tan, Po Hong, Saleeb, Andrew, Stucky, Chee-Chee, Bagaria, Sanjay P, Gabriel, Emmanuel , Grotz, Travis E. , Wasif, Nabil , Miller, Max , Thompson, Emily , Miller, Richard Max , Thompson, Emily R , Grotz, Travis E , Gabriel, Emmanuel M , Saleeb, Andrew G. , Thompson, Emily R., Fong, Zhi Ven , Bagaria, Sanjay P.

Mayo Clinic

Journal of Surgical Oncology | April 30, 2026 | Volume: 134 | Issue: 1 | Pages: 91-100

10.1002/jso.70274 | PMID 42057320 Get It

ABSTRACT Background and Objectives NCCN guidelines recommend right hemicolectomy (RHC) for appendiceal neuroendocrine tumors (aNETs) > 2 cm and observation for < 1 cm. However, optimal surgical management of 1–2 cm tumors remains controversial. This study compared long‐term survival and recurrence between patients undergoing RHC versus appendectomy (APY) for 1–2 cm aNETs. Methods Patients with pathologically confirmed 1–2 cm aNETs treated at three Mayo Clinic sites (1972–2024) were included. Primary outcomes were recurrence and all‐cause mortality after resection. Associations with lymph node (LN) metastasis were assessed in patients with lymphadenectomy. Results Sixty‐five patients were identified: 29 (45%) underwent APY, 35 (54%) RHC, and one ileocecectomy. Median age at diagnosis was 39 years; 71% were female and 94% white. LN positivity was 15.2% for tumors with nodes examined. Tumor size > 1.5 cm, stage T3/T4, and lymphovascular invasion were not associated with nodal metastasis. No survival differences were observed between APY and RHC. LN positivity did not impact survival. No recurrences occurred during a median follow‐up of 6.25 years (IQR 2.44–12.63). Conclusions Among patients with 1–2 cm aNETs, RHC conferred no survival benefit over APY. Absence of recurrence and the limited prognostic value of nodal disease suggest APY alone may suffice for this population.
Response: Clues to revising the conventional diagnostic algorithm for endometriosis
Spiers, Andrew , Roman, Horace, Wasson, Megan , Chapron, Charles, Rousset, Pascal, Golfier, François, Fauvet, R. , Delbos, Léa , Fernandez, Hervé, Descamps, Philippe, Bendifallah, Sofiane, Chapron, Charles , Rousset, Pascal , Golfier, François , Fernandez, Hervé , Descamps, Philippe , Bendifallah, Sofiane

Mayo Clinic

International Journal of Gynecology & Obstetrics | April 29, 2026 | Volume: 173 | Issue: 3 | Pages: 1654-1656

10.1002/ijgo.71050 | PMID 42053435 Get It

Current Topics in Learning and Development in Radiology: AJR Expert Panel Narrative Review
Moriarity, Andy, Goldberg-Stein, Shlomit, Cook, Tessa S. , Sharpe, Richard E. , Moriarity, Andrew K. , Goldberg-Stein, Shlomit A. , Giess, Catherine S. , Shinagare, Atul Bhanudas , Khorasani, Ramin

Mayo Clinic

American Journal of Roentgenology | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.2214/ajr.24.31798 | PMID 42053390 Get It

Percutaneous spinal stimulation to enhance gait and alleviate functional impairments in multiple sclerosis: A pilot study
Jahanian, Omid , Asp, Anders J., Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Hogen, Cecilia A., Mills, Candee J. , Thoreson, Andrew R. , Grahn, Peter J. , Fernandez, Katrina A, Tobin, W Oliver , Fernandez, K A , Jahanian, Omid , Asp, Anders J., Solinsky, Ryan , Kaufman, Kenton R. , Zhao, Kristin D. , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 29, 2026 | Volume: 12 | Issue: 2 | Pages: No page available

10.1177/20552173261432301 | PMID 42112095 Get It

Objective To evaluate the feasibility and potential efficacy of percutaneous spinal stimulation (epidural stimulation, ES) combined with task-specific training to reduce spasticity and improve gait and balance in individuals with progressive multiple sclerosis (MS). Methods Two men with progressive MS (EDSS 6.5) underwent ES lead implantation targeting the lower spinal cord, followed by one month of rehabilitation involving 12 ES-assisted training sessions. Assessments included instrumented gait analysis, Modified Ashworth Scale (MAS), pendulum test, and static balance testing performed at baseline, and at end of the study with ES-Off and ES-On conditions. Results Participant 1, with spastic hemiparetic gait, demonstrated improved lower extremity joint kinematics and muscle activation during gait, reduced knee extensor spasticity, and enhanced functional movement patterns with ES-On. Participant 2, with significant paraparesis and minimal spasticity, showed limited gait changes but experienced marked improvements in static balance, particularly under eyes-closed conditions. No adverse events were reported. Conclusion This pilot study demonstrates the feasibility and tolerability of ES paired with task-specific training in progressive MS. Participant-specific responses were observed, including improvements in gait kinematics, neuromuscular activation, spasticity, or balance; however, spatiotemporal gait parameters did not improve. These preliminary findings highlight response heterogeneity and the need for individualized ES parameter tuning. Trial registry name and URL: https://clinicaltrials.gov/study/NCT06019611
Disparities in Hearing Screening Practices in Minnesota Elementary Schools
Sajjadi, Autefeh , Kim, E S, Marcus, Kathryn S. , Todatry, Soorya, Hable, Nicholas, Roby, Brianne, Meyer, Abby C., Redmann, Andrew, Herd, Hannah, Maher, Rebecca, Chinnadurai, Siva, Nickel, Amanda , Jayawardena, Asitha , Kim, Elizabeth , Roby, Brianne , Todatry, Soorya , Hable, Nicholas, Roby, Brianne Barnett , Redmann, Andrew J. , Herd, Hannah

Mayo Clinic

The Laryngoscope | April 29, 2026 | Volume: 136 | Issue: 9 | Pages: 4064-4071

10.1002/lary.70566 | PMID 42049482 Get It

ABSTRACT Objective Identifying and addressing pediatric hearing loss is critical to supporting a child's development. School‐based hearing screening is a mainstay of timely identification of hearing loss. The objectives of this study were to characterize the current hearing screening practices in public, charter, and private elementary schools in Minnesota. Methods This was a cross‐sectional survey with data collected between March and June 2023. Surveys assessed the presence of standardized hearing screening processes and compliance with American Academy of Audiology (AAA) or Minnesota Department of Health (MDH) guidelines. Results About 146 public schools, 43 charter schools, and 60 private schools met inclusion criteria and responded to the survey. There was a statistically significant difference in the rate of standardized screening between school types ( χ 2 = 18.06; p < 0.001). Only 10.44% ( n = 26) of schools completed hearing screenings per AAA guidelines, and even fewer, 4.82% ( n = 12), completed hearing screenings according to MDH guidelines. The odds of screening per AAA or MDH guidelines were 3.50 times higher in charter schools compared to public schools (95% CI: 1.14, 10.73) and 4.61 times higher in private schools compared to public schools (95% CI: 1.73, 12.26). Conclusion There is a lack of standardization in hearing screening processes in Minnesota elementary schools. Adherence to screening per AAA or MDH recommendations is low in all types of elementary schools. Charter and private schools were more likely than public schools to screen per AAA or MDH guidelines. Overall, our data demonstrate an opportunity for improvement in school‐based hearing screening. Level of Evidence N/A.